MCID: CLR003
MIFTS: 50

Clear Cell Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Clear Cell Adenocarcinoma

MalaCards integrated aliases for Clear Cell Adenocarcinoma:

Name: Clear Cell Adenocarcinoma 12 15 17
Mesonephroma 12 43 71
Water-Clear Cell Adenocarcinoma 12 71
Adenocarcinoma, Clear Cell 43 71
Mesonephroid Clear Cell Carcinoma 12
Water-Clear Cell Carcinoma 12
Adenocarcinoma Clear Cell 54
Mesonephroma, Malignant 12
Malignant Mesonephroma 12
Wolffian Duct Neoplasm 12
Mesonephric Tumor 71

Classifications:



External Ids:

Disease Ontology 12 DOID:4468
UMLS 71 C0025490 C0206681 C0334322 more

Summaries for Clear Cell Adenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells which have clear cytoplasm.

MalaCards based summary : Clear Cell Adenocarcinoma, also known as mesonephroma, is related to urethra clear cell adenocarcinoma and ovarian clear cell adenocarcinoma. An important gene associated with Clear Cell Adenocarcinoma is MUC16 (Mucin 16, Cell Surface Associated), and among its related pathways/superpathways are Gastric cancer and Human Embryonic Stem Cell Pluripotency. The drugs Lenograstim and Topotecan have been mentioned in the context of this disorder. Affiliated tissues include ovary, cervix and kidney, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 74 Clear-cell adenocarcinoma is a type of adenocarcinoma that shows clear... more...

Related Diseases for Clear Cell Adenocarcinoma

Diseases related to Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 357)
# Related Disease Score Top Affiliating Genes
1 urethra clear cell adenocarcinoma 34.6 KLK3 AMACR
2 ovarian clear cell adenocarcinoma 32.9 TP53 PIK3CA NAPSA HOXA10 HNF1B ARID1A
3 epithelial-myoepithelial carcinoma 32.4 TP53 PIK3CA KRT7
4 wolffian duct adenoma 31.9 PAX8 PAX2 KRT7 KLK3 AMACR
5 bladder clear cell adenocarcinoma 31.6 TP53 PAX8 PAX2 NAPSA KRT7 KRT20
6 endometriosis 31.0 TP53 MUC16 HOXA10 HNF1B
7 cervical adenocarcinoma 30.7 TP53 KRT7 KRT20
8 appendix adenocarcinoma 30.7 KRT7 KRT20
9 clear cell adenofibroma 30.5 PIK3CA NAPSA ARID1A
10 endodermal sinus tumor 30.5 MUC16 KRT7 KLK3 ACP3
11 urethral diverticulum 30.5 PAX8 KRT7 KLK3 AMACR
12 ovarian clear cell adenofibroma 30.4 PIK3CA NAPSA
13 urethra adenocarcinoma 30.4 KLK3 AMACR
14 male urethral cancer 30.3 KLK3 AMACR
15 benign mesothelioma 30.3 PAX8 KRT7
16 papillary adenocarcinoma 30.1 TP53 MUC16 KRT7
17 carcinosarcoma 30.1 TP53 PIK3CA PAX8 KRT7
18 adenocarcinoma 30.1 TP53 SMAD4 SMAD3 PIK3CA NAPSA KRT7
19 serous cystadenocarcinoma 30.0 TP53 PIK3CA PAX8 MUC16 KRT7 ARID1A
20 myoma 30.0 TP53 MUC16 HOXA10
21 adenoma 29.9 TP53 SMAD4 SMAD3 PIK3CA KRT7 KRT20
22 renal hypodysplasia/aplasia 1 29.9 PAX8 PAX2 HNF1B
23 cystadenocarcinoma 29.8 TP53 PIK3CA PAX8 MUC16 KRT7
24 ovarian brenner tumor 29.8 MUC16 KRT7 KRT20
25 mucinous adenocarcinoma 29.8 TP53 MUC16 KRT7 KRT20 AMACR
26 gallbladder adenocarcinoma 29.7 TP53 PIK3CA KRT20
27 adenofibroma 29.6 TP53 PAX8 NAPSA MUC16 KRT7 ARID1A
28 polycystic liver disease 1 with or without kidney cysts 29.6 MUC16 KRT7 KRT20 HNF1B
29 dysgerminoma 29.6 PTHLH KRT7 KRT20
30 small cell carcinoma 29.5 TP53 KRT7 KRT20 KLK3
31 nephrogenic adenoma 29.5 PAX8 PAX2 KRT7 KLK3 AMACR
32 squamous cell carcinoma 29.5 TP53 SMAD4 PTHLH PIK3CA KRT7
33 transitional cell carcinoma 29.4 TP53 PIK3CA KRT7 KRT20 KLK3
34 bladder adenocarcinoma 29.2 KRT7 KRT20 KLK3 AMACR
35 wilms tumor 1 29.2 TP53 PAX8 PAX2 KRT7
36 ovarian clear cell carcinoma 29.2 TP53 PIK3CA NAPSA MUC16 KRT7 HNF1B
37 cholangiocarcinoma 29.1 TP53 SMAD4 PIK3CA KRT7 KRT20
38 urinary tract obstruction 29.1 SMAD3 SMAD2 PIK3CA PAX2 KLK3
39 endosalpingiosis 29.1 TP53 PAX8 PAX2 KRT7
40 suppression of tumorigenicity 12 29.0 TP53 SMAD4 PIK3CA KRT7 KLK3 AMACR
41 intrahepatic cholangiocarcinoma 29.0 TP53 SMAD4 KRT7 KRT20 ARID1A
42 glandular cystitis 28.9 TP53 KRT7 KRT20 KLK3 AMACR
43 gastric adenocarcinoma 28.7 TP53 SMAD4 PIK3CA MUC16 KRT7 KRT20
44 endocervical adenocarcinoma 28.5 TP53 PIK3CA PAX8 PAX2 KRT7 KRT20
45 clear cell renal cell carcinoma 28.4 TP53 PAX8 PAX2 KRT7 ARID1A AMACR
46 ovary adenocarcinoma 28.4 TP53 SMAD4 PIK3CA PAX8 MUC16 KRT7
47 ovarian serous cystadenocarcinoma 28.2 TP53 SMAD4 PIK3CA PAX8 PAX2 MUC16
48 renal cell carcinoma, papillary, 1 28.2 TP53 PIK3CA PAX8 PAX2 KRT7 AMACR
49 lung cancer susceptibility 3 28.2 TP53 SMAD4 PIK3CA NAPSA MUC16 KRT7
50 ovarian cancer 27.8 TP53 SMAD4 SMAD3 SMAD2 SLC22A16 PIK3CA

Graphical network of the top 20 diseases related to Clear Cell Adenocarcinoma:



Diseases related to Clear Cell Adenocarcinoma

Symptoms & Phenotypes for Clear Cell Adenocarcinoma

GenomeRNAi Phenotypes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-114 9.44 ARID1A
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.44 PIK3CA
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-157 9.44 PIK3CA
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-16 9.44 PIK3CA
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 9.44 PIK3CA
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 9.44 PIK3CA
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 9.44 PIK3CA SMAD2
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-2 9.44 SMAD2
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.44 PIK3CA
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 9.44 PIK3CA
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 9.44 PIK3CA
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.44 PIK3CA

MGI Mouse Phenotypes related to Clear Cell Adenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.17 ARID1A HOXA10 KLK3 PAX2 PAX8 PIK3CA
2 cellular MP:0005384 10.14 ARID1A HNF1B KRT7 PAX2 PAX8 PIK3CA
3 endocrine/exocrine gland MP:0005379 10.03 ACP3 ARID1A HNF1B HOXA10 PAX2 PAX8
4 embryo MP:0005380 9.97 ARID1A HNF1B PAX2 PAX8 PIK3CA SMAD2
5 craniofacial MP:0005382 9.91 ARID1A PAX8 PTHLH SMAD2 SMAD3 SMAD4
6 neoplasm MP:0002006 9.76 ACP3 ARID1A PIK3CA PTHLH SMAD2 SMAD3
7 renal/urinary system MP:0005367 9.56 HNF1B KRT7 PAX2 PAX8 PTHLH SMAD3
8 reproductive system MP:0005389 9.36 ACP3 ARID1A HOXA10 PAX2 PAX8 PIK3CA

Drugs & Therapeutics for Clear Cell Adenocarcinoma

Drugs for Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 114)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3 135968-09-1
2
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
3
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
4
Gemcitabine Approved Phase 3 95058-81-4 60750
5
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
6
Olaparib Approved Phase 3 763113-22-0 23725625
7
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
8
Rucaparib Approved, Investigational Phase 3 283173-50-2 9931954
9
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
10
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
11
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
12
Pembrolizumab Approved Phase 3 1374853-91-4
13
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
14
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
15 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
16
Cediranib Investigational Phase 3 288383-20-0 9933475
17
Maleic acid Experimental, Investigational Phase 3 110-17-8, 110-16-7 444972
18 Adjuvants, Immunologic Phase 3
19 Trace Elements Phase 3
20 Carotenoids Phase 3
21 Micronutrients Phase 3
22 topoisomerase I inhibitors Phase 2, Phase 3
23 Tubulin Modulators Phase 2, Phase 3
24 Antimitotic Agents Phase 2, Phase 3
25 Protein Kinase Inhibitors Phase 3
26 Anti-Infective Agents Phase 3
27 Antiviral Agents Phase 3
28 taxane Phase 3
29 Immunosuppressive Agents Phase 3
30 Antimetabolites Phase 3
31 Hypoglycemic Agents Phase 2, Phase 3
32 Poly(ADP-ribose) Polymerase Inhibitors Phase 3
33 Tin Fluorides Phase 3
34 Albumin-Bound Paclitaxel Phase 3
35
Liposomal doxorubicin Phase 2, Phase 3 31703
36 Anti-Bacterial Agents Phase 2, Phase 3
37 Antibiotics, Antitubercular Phase 2, Phase 3
38 Immunologic Factors Phase 2, Phase 3
39 Endothelial Growth Factors Phase 2, Phase 3
40 Immunoglobulins, Intravenous Phase 2, Phase 3
41 Mitogens Phase 2, Phase 3
42 Antibodies, Monoclonal Phase 2, Phase 3
43 Immunoglobulin G Phase 2, Phase 3
44
Vinblastine Approved Phase 2 865-21-4 241903 13342
45
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
46
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
47
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
48
nivolumab Approved Phase 2 946414-94-4
49
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
50
Nintedanib Approved Phase 2 656247-17-5 56843413

Interventional clinical trials:

(show top 50) (show all 84)
# Name Status NCT ID Phase Drugs
1 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
3 An International, Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Investigate Whether TroVax, Added to First-line Standard of Care Therapy, Prolongs the Survival of Patients With Locally Advanced or Metastatic Clear Cell Renal Adenocarcinoma. Completed NCT00397345 Phase 3
4 Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
5 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Recruiting NCT03422198 Phase 3
6 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Recruiting NCT00719303 Phase 3
7 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
8 Randomized Phase III Trial of the Need for Adjuvant Chemotherapy in Stage I Epithelial Ovarian Cancer After Comprehensive Staging Surgery Recruiting NCT04063527 Phase 3 adjuvant chemotherapy
9 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
10 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
11 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
12 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
13 A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
14 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
15 Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients Not yet recruiting NCT04227522 Phase 3 Rucaparib;Placebos
16 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Suspended NCT03914612 Phase 3 Carboplatin;Paclitaxel
17 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer Suspended NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
18 Interleukin-2, Interferon Alpha,Capecitabine and Vinblastin for Treatment of Metastatic Renal Cell Carcinoma: A Multicenter Study Unknown status NCT00226798 Phase 2 Capecitabine (Xeloda)
19 MEDI4736 Combinations in Metastatic Renal Cell Carcinoma Unknown status NCT02819596 Phase 2 Savolitinib;MEDI4736;Tremelimumab
20 A Phase II Evaluation of SU11248 (Sunitinib Malate) (NSC #736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma Completed NCT00979992 Phase 2 Sunitinib Malate
21 A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum Completed NCT02315430 Phase 2 Cabozantinib S-malate
22 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
23 Evaluation of the Efficacy of Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Completed NCT01824615 Phase 2 Sunitinib
24 A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
25 A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium Completed NCT01210222 Phase 2
26 A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01225887 Phase 2 Nintedanib
27 A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma Completed NCT00025467 Phase 2 thalidomide
28 Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas Completed NCT01914510 Phase 2 ENMD-2076
29 A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
30 A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01011933 Phase 2 Selumetinib
31 A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
32 A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01132820 Phase 2 Cediranib Maleate
33 A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
34 A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00888173 Phase 2 Brivanib Alaninate
35 A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01642082 Phase 2
36 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
37 EVALUATION OF PACLITAXEL (TAXOL) IN PERSISTENT OR RECURRENT NON-SQUAMOUS CELL CARCINOMA OF THE CERVIX AND VAGINA Completed NCT00002562 Phase 2 paclitaxel
38 Clinical Trial Phase II (Single Centre Study) : A Preliminary Study of the Safety, Immunogenicity, and Clinical Efficacy of TroVax Given in Conjunction With Interleukin 2 (IL-2) in the Treatment of Stage IV Renal Cell Cancer Completed NCT00083941 Phase 2
39 Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer Recruiting NCT03241745 Phase 2 Nivolumab
40 A Phase 1b/2a Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Advanced Malignancies Recruiting NCT03297424 Phase 1, Phase 2 PLX2853
41 BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas Recruiting NCT03355976 Phase 2 Nivolumab;Ipilimumab
42 A Multicentre Phase II Randomised Trial of Durvalumab (MEDI4736) Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas (MOCCA) Recruiting NCT03405454 Phase 2 durvalumab;standard chemotherapy
43 Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
44 An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Recruiting NCT03648489 Phase 2 Paclitaxel;TAK228
45 A Phase I/II Study of Olaparib With Entinostat in the Treatment of Recurrent, Platinum-Refractory or Resistant, Homologous Recombination Repair Proficient Ovarian, Primary Peritoneal, and Fallopian Tube Cancers Recruiting NCT03924245 Phase 1, Phase 2 Entinostat;Olaparib
46 A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
47 A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus Recruiting NCT00492778 Phase 2 Cisplatin
48 A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Recruiting NCT02866370 Phase 2 Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
49 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
50 A Phase II Trial of DCTD-Sponsored Dasatinib in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression Active, not recruiting NCT02059265 Phase 2 Dasatinib

Search NIH Clinical Center for Clear Cell Adenocarcinoma

Cochrane evidence based reviews: mesonephroma

Genetic Tests for Clear Cell Adenocarcinoma

Anatomical Context for Clear Cell Adenocarcinoma

MalaCards organs/tissues related to Clear Cell Adenocarcinoma:

40
Ovary, Cervix, Kidney, Colon, Lymph Node, Lung, Prostate

Publications for Clear Cell Adenocarcinoma

Articles related to Clear Cell Adenocarcinoma:

(show top 50) (show all 984)
# Title Authors PMID Year
1
Expression of glucose transporters in epithelial ovarian carcinoma: correlation with clinical characteristics and tumor angiogenesis. 61 54
17611657 2007
2
MMAC tumor supressor gene expression in ovarian endometriosis and ovarian adenocarcinoma. 61 54
17713092 2007
3
The autocrine effect of activin A on human ovarian clear cell adenocarcinoma cells. 61 54
16820918 2006
4
PTEN expression in clear cell adenocarcinoma of the ovary. 54 61
16290000 2006
5
Clear cell adenocarcinoma of the female urethra showing strong immunostaining for prostate-specific antigen. 54 61
11251541 2001
6
Hypercalcemia due to parathyroid hormone-related protein produced by primary ovarian clear cell adenocarcinoma: case report. 54 61
10637074 2000
7
Clear cell adenocarcinoma and nephrogenic adenoma of the urethra and urinary bladder: a histopathologic and immunohistochemical comparison. 54 61
9865832 1998
8
Ovarian vein vs peripheral blood CA125 serum levels: a comparative study. 54 61
9234924 1997
9
[A case of clear cell adenocarcinoma of the female urethra]. 61 54
7645457 1995
10
Clear cell adenocarcinoma of the female urethra showing positive staining with antibodies to prostate-specific antigen and prostatic acid phosphatase. 54 61
7536368 1995
11
Nephrogenic adenoma of the prostatic urethra involving the prostate gland: a clinicopathologic and immunohistochemical study of eight cases. 61 54
7512941 1994
12
Clear cell adenocarcinoma arising from the abdominal wall after cesarean section in a patient with uterine adenomyosis. 61
32280445 2020
13
Three female patients with a periurethral mass: from various complaints to rare pathology. 61
32276998 2020
14
Personalized chemotherapy in clear cell adenocarcinoma of the urethra: A case report. 61
32355644 2020
15
Identification of Candidate Genes Associated with Susceptibility to Ovarian Clear Cell Adenocarcinoma Using cis-eQTL Analysis. 61
32316112 2020
16
Primary Clear Cell Adenocarcinoma of the Head and Neck: A Population-Based Analysis. 61
32013719 2020
17
A Rare Case of Clear Cell Adenocarcinoma of the Cervix with No Intrauterine Diethylstilbestrol Exposure. 61
32461864 2020
18
Fertility-preserving local excision under a hysteroscope with combined chemotherapy in a 6-year-old child with clear cell adenocarcinoma of the cervix: A case report and review of the literature. 61
32000369 2020
19
Relationship between clinical and histopathological features of patients undergoing cholecystectomy. 61
32550945 2020
20
Fertility-sparing surgery of cervical cancer >2 cm (International Federation of Gynecology and Obstetrics 2009 stage IB1-IIA) after neoadjuvant chemotherapy. 61
31744889 2020
21
Mixed Serous and Clear Cell Adenocarcinoma of the Ovary Presenting with Symptomatic Hypercalcemia: A Case Report and Clinical Considerations. 61
32069206 2020
22
Clear Cell Adenocarcinoma of the Urinary Bladder Is a Glycogen-Rich Tumor with Poorer Prognosis. 61
31947882 2020
23
Distal Fibular Reconstruction Using Iliac Grafting and Emslie-Vidal's Ligamentoplasty after Exeresis of Single Renal Carcinoma Metastasis. 61
32181039 2020
24
Molecular profiling of clear cell adenocarcinoma of the urinary tract. 61
31372739 2019
25
Endometriosis Malignant Transformation Review: Rhabdomyosarcoma Arising From an Endometrioma. 61
31624455 2019
26
Primary Clear Cell Adenocarcinoma of the Vulva: A Case Study With Mutation Analysis and Literature Review. 61
31104528 2019
27
Germline mutation and aberrant transcripts of WWOX in a syndrome with multiple primary tumors. 61
31056747 2019
28
Second primary uterine malignancies after radiation therapy for cervical cancer. 61
31069490 2019
29
Prenatal diethylstilbestrol exposure and cancer risk in women. 61
29124779 2019
30
Radiotherapy for isolated recurrent epithelial ovarian cancer: A single institutional experience. 61
30843318 2019
31
POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure. 61
30733993 2019
32
Clear cell adenocarcinoma of the lung: a SEER analysis. 61
31106129 2019
33
Metastatic Clear Cell Renal Carcinoma Without Evidence of a Primary Renal Tumour Mimicking Advanced Stage of Malignant Lung Tumour. 61
31064187 2019
34
Two Cases of Rare Pancreatic Malignancies. 61
31338486 2019
35
Uncommon site of metastasis from renal cell carcinoma: Case report. 61
30849687 2019
36
Clear cell adenocarcinoma of the lung: a population-based study. 61
30774428 2019
37
Primary Clear Cell Adenocarcinoma of the Cervix: A Clinical Analysis of 18 Cases without Exposure to Diethylstilbestrol. 61
31049066 2019
38
Early stage clear cell adenocarcinoma of the colon examined in detail with image-enhanced endoscopy: a case report. 61
30062544 2018
39
Unusual BK polyomavirus-associated urologic malignancies in renal transplant recipients: Report of two cases and review of the literature. 61
30208262 2018
40
PBN11-8, a Cytotoxic Polypeptide Purified from Marine Bacillus, Suppresses Invasion and Migration of Human Hepatocellular Carcinoma Cells by Targeting Focal Adhesion Kinase Pathways. 61
30960968 2018
41
Three cases of clear-cell adenocarcinoma arising from endometrioma during hormonal treatments. 61
29998468 2018
42
Ovarian Clear Cell Adenofibroma of Low Malignant Potential Developing Into Clear Cell Adenocarcinoma. 61
29551085 2018
43
Unusual Features of Clear Cell Adenocarcinoma of the Female Urethra: A Case Report and Literature Review. 61
29977425 2018
44
Fairly rare clear cell adenocarcinoma mimicking liver cancer: a case report. 61
30117003 2018
45
The Endometriotic Tumor Microenvironment in Ovarian Cancer. 61
30087267 2018
46
Morphologic and Immunohistochemical Study of Clear Cell Carcinoma of the Uterine Endometrium and Cervix in Comparison to Ovarian Clear Cell Carcinoma. 61
28796747 2018
47
Clear cell adenocarcinoma of female urethra: A case report. 61
29888186 2018
48
[Two Cases of Clear Cell Adenocarcinoma Arising in Urethral Diverticulum]. 61
30089340 2018
49
Synchronous occurrence of primary right ovarian endometrioid adenocarcinoma and primary left ovarian clear cell adenocarcinoma: A case report. 61
29979406 2018
50
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma with fetal gut differentiation: a rare case report and literature review. 61
29933751 2018

Variations for Clear Cell Adenocarcinoma

Copy number variations for Clear Cell Adenocarcinoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 218693 7 116312458 116438439 Amplification MET Clear cell adenocarcinoma
2 266962 Y 174481503 174538309 Duplication AZF Clear cell adenocarcinoma

Expression for Clear Cell Adenocarcinoma

Search GEO for disease gene expression data for Clear Cell Adenocarcinoma.

Pathways for Clear Cell Adenocarcinoma

Pathways related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.51 TP53 SMAD4 SMAD3 SMAD2 PIK3CA ARID1A
2
Show member pathways
12.42 SMAD4 SMAD3 SMAD2 HNF1B
3
Show member pathways
12.4 SMAD4 SMAD3 SMAD2 PTHLH HNF1B
4
Show member pathways
12.37 TP53 SMAD4 SMAD3 SMAD2 PIK3CA
5 12.31 TP53 SMAD4 SMAD3 SMAD2
6
Show member pathways
12.29 TP53 SMAD4 SMAD3 SMAD2
7
Show member pathways
12.25 TP53 SMAD4 SMAD3 SMAD2 PIK3CA PAX8
8
Show member pathways
12.24 TP53 SMAD3 PIK3CA KLK3
9 12.17 SMAD4 SMAD3 SMAD2 PAX2
10 12.09 TP53 SMAD4 SMAD3 SMAD2
11 12.06 TP53 SMAD4 SMAD3 SMAD2 PIK3CA
12 12.05 TP53 SMAD3 SMAD2 PIK3CA
13 12 SMAD4 SMAD3 SMAD2 PIK3CA
14 11.96 TP53 SMAD4 SMAD3 SMAD2
15 11.89 TP53 SMAD4 SMAD3 SMAD2 PIK3CA PAX8
16 11.84 SMAD4 SMAD3 SMAD2
17 11.84 TP53 SMAD4 SMAD3 PIK3CA
18 11.82 SMAD4 SMAD3 SMAD2
19
Show member pathways
11.82 SMAD4 SMAD3 SMAD2
20
Show member pathways
11.8 SMAD4 SMAD3 SMAD2
21 11.8 SMAD4 SMAD3 KLK3
22 11.74 TP53 SMAD4 SMAD3
23
Show member pathways
11.72 SMAD4 SMAD3 SMAD2
24 11.71 SMAD4 SMAD3 SMAD2
25 11.71 SMAD4 SMAD3 SMAD2 PIK3CA
26 11.68 SMAD4 SMAD3 SMAD2
27
Show member pathways
11.65 SMAD4 SMAD3 SMAD2
28 11.64 TP53 SMAD4 SMAD3 SMAD2
29 11.62 TP53 PIK3CA ARID1A
30 11.56 SMAD4 SMAD3 SMAD2
31
Show member pathways
11.49 SMAD4 SMAD3 SMAD2 PIK3CA
32 11.48 SMAD4 SMAD3 SMAD2
33 11.48 TP53 SMAD4 SMAD3
34
Show member pathways
11.46 SMAD4 SMAD3 SMAD2
35 11.41 TP53 SMAD3 SMAD2
36
Show member pathways
11.16 SMAD4 SMAD3 PIK3CA
37 11.11 SMAD4 SMAD3 SMAD2
38 11.01 SMAD4 SMAD3 SMAD2
39 10.71 SMAD4 SMAD3 SMAD2
40 10.59 SMAD4 SMAD3 SMAD2

GO Terms for Clear Cell Adenocarcinoma

Cellular components related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.21 TP53 SMAD4 SMAD3 SMAD2 PTHLH POU6F1
2 transcription factor complex GO:0005667 9.43 TP53 SMAD4 SMAD3 SMAD2 HOXA10 HNF1B
3 SMAD protein complex GO:0071141 9.33 SMAD4 SMAD3 SMAD2
4 activin responsive factor complex GO:0032444 9.32 SMAD4 SMAD2
5 nuclear chromatin GO:0000790 9.32 TP53 SMAD4 SMAD3 SMAD2 POU6F1 PAX8
6 heteromeric SMAD protein complex GO:0071144 9.26 SMAD3 SMAD2

Biological processes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 10.24 TP53 SMAD4 SMAD3 SMAD2 POU6F1 PAX8
2 negative regulation of transcription by RNA polymerase II GO:0000122 10.13 TP53 SMAD4 SMAD3 SMAD2 POU6F1 HNF1B
3 positive regulation of transcription by RNA polymerase II GO:0045944 10.09 TP53 SMAD4 SMAD3 SMAD2 POU6F1 PAX8
4 negative regulation of cell proliferation GO:0008285 10.06 TP53 SMAD4 SMAD3 SMAD2 PTHLH
5 protein deubiquitination GO:0016579 9.99 TP53 SMAD4 SMAD3 SMAD2
6 in utero embryonic development GO:0001701 9.97 TP53 SMAD4 SMAD3 SMAD2
7 positive regulation of transcription, DNA-templated GO:0045893 9.97 TP53 SMAD4 SMAD3 SMAD2 PAX8 PAX2
8 anterior/posterior pattern specification GO:0009952 9.88 SMAD4 SMAD2 HOXA10 HNF1B
9 liver development GO:0001889 9.86 SMAD3 PIK3CA HNF1B
10 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.86 TP53 SMAD3 SMAD2
11 transforming growth factor beta receptor signaling pathway GO:0007179 9.86 TP53 SMAD4 SMAD3 SMAD2
12 single fertilization GO:0007338 9.85 SMAD4 SLC22A16 HOXA10
13 SMAD protein signal transduction GO:0060395 9.83 SMAD4 SMAD3 SMAD2
14 positive regulation of epithelial to mesenchymal transition GO:0010718 9.8 SMAD4 SMAD3 SMAD2
15 branching involved in ureteric bud morphogenesis GO:0001658 9.8 SMAD4 PAX8 PAX2
16 developmental growth GO:0048589 9.74 SMAD4 SMAD3 SMAD2
17 secondary palate development GO:0062009 9.69 SMAD4 SMAD2
18 mesonephros development GO:0001823 9.69 PAX8 PAX2
19 nodal signaling pathway GO:0038092 9.68 SMAD3 SMAD2
20 primary miRNA processing GO:0031053 9.67 SMAD3 SMAD2
21 pericardium development GO:0060039 9.67 SMAD3 SMAD2
22 embryonic foregut morphogenesis GO:0048617 9.66 SMAD3 SMAD2
23 mesonephric tubule development GO:0072164 9.65 PAX8 HNF1B
24 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.65 PAX8 PAX2
25 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.64 PAX8 PAX2
26 metanephric epithelium development GO:0072207 9.63 PAX8 PAX2
27 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.63 SMAD4 SMAD3 SMAD2
28 metanephric nephron tubule formation GO:0072289 9.62 PAX8 PAX2
29 metanephric distal convoluted tubule development GO:0072221 9.61 PAX8 PAX2
30 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.61 PAX8 PAX2
31 regulation of transforming growth factor beta2 production GO:0032909 9.6 SMAD4 SMAD3
32 nephric duct formation GO:0072179 9.59 PAX2 HNF1B
33 SMAD protein complex assembly GO:0007183 9.58 SMAD4 SMAD3 SMAD2
34 endoderm development GO:0007492 9.56 SMAD4 SMAD3 SMAD2 HNF1B
35 positive regulation of metanephric DCT cell differentiation GO:2000594 9.55 PAX8 PAX2
36 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 9.54 PAX8 PAX2
37 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 9.52 PAX8 PAX2
38 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 9.51 PAX8 PAX2
39 pronephros development GO:0048793 9.5 PAX8 PAX2 HNF1B
40 paraxial mesoderm morphogenesis GO:0048340 9.49 SMAD3 SMAD2
41 pronephric field specification GO:0039003 9.48 PAX8 PAX2
42 regulation of binding GO:0051098 9.33 SMAD4 SMAD3 SMAD2
43 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.13 PAX8 PAX2 HNF1B
44 gastrulation GO:0007369 9.02 TP53 SMAD4 SMAD3 SMAD2 ARID1A

Molecular functions related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 10.1 TP53 SMAD4 SMAD3 SMAD2 POU6F1 PAX8
2 sequence-specific DNA binding GO:0043565 9.99 SMAD4 SMAD3 POU6F1 PAX8 HOXA10 HNF1B
3 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.95 TP53 SMAD4 SMAD3 SMAD2 PAX8 HOXA10
4 DNA-binding transcription factor activity GO:0003700 9.92 TP53 SMAD4 SMAD3 SMAD2 POU6F1 PAX8
5 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.89 TP53 SMAD4 SMAD3 POU6F1 HNF1B
6 transcription regulatory region sequence-specific DNA binding GO:0000976 9.83 TP53 SMAD4 SMAD3 PAX8 PAX2
7 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.8 TP53 SMAD4 SMAD3 SMAD2 POU6F1 PAX8
8 transcription regulatory region DNA binding GO:0044212 9.63 TP53 SMAD4 SMAD3 PAX8 PAX2 HNF1B
9 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.61 TP53 SMAD4 SMAD3 SMAD2 POU6F1 PAX8
10 co-SMAD binding GO:0070410 9.55 SMAD3 SMAD2
11 I-SMAD binding GO:0070411 9.54 SMAD4 SMAD2
12 R-SMAD binding GO:0070412 9.54 SMAD4 SMAD3 SMAD2
13 primary miRNA binding GO:0070878 9.52 SMAD3 SMAD2
14 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 9.46 SMAD3 SMAD2
15 proximal promoter sequence-specific DNA binding GO:0000987 9.02 SMAD4 SMAD3 SMAD2 PAX2 HNF1B

Sources for Clear Cell Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....